Drugs included in this group are cholinesterase inhibitors (donepezil, rivastigmine, and galantamine), which are approved for treating mild to moderate AD, and memantine, an NMDA receptor antagonist, which is used to treat patients with moderate to severe AD. This evidence concerns the gene BCHE and Alzheimer disease.